Studies have also shown that treatment with Sigmar1 agonists (such PRE-084) reduced infarct volume, neurological deficits, levels of pro-inflammatory cytokines, and enhanced the actions of anti-inflammatory cytokines after embolic stroke in rats (Allahtavakoli and Jarrott, 2011). This evidence concerns the gene SIGMAR1 and stroke disorder.